论文部分内容阅读
目的探讨氨溴索在早产儿呼吸窘迫征防治中的临床效果。方法对我科收治的117例早产儿进行分析,随机分为2组,对照组采用常规治疗,治疗组在对照组基础上采用盐酸氨溴索治疗。结果治疗组中发生RDS16例(27.1%),对照组中发生RDS27例(46.6%),两组比较有明显差异(P<0.05)。治疗组在病情稳定、呼吸改善时间、治愈率比较中明显优于对照组(P<0.01),在并发症发生率、死亡率比较中明显低于对照组(P<0.05)。结论氨溴索能有效促进肺表面活性物质生成和分泌,促进肺发育成熟,改善通气,对提高患儿存活率与生存质量具有明显的疗效和意义。
Objective To investigate the clinical efficacy of ambroxol in the prevention and treatment of respiratory distress syndrome in preterm infants. Methods 117 cases of premature infants admitted to our department were analyzed and randomly divided into two groups. The control group was treated with conventional therapy. The treatment group was treated with ambroxol hydrochloride on the basis of the control group. Results There were 16 cases (27.1%) of RDS in the treatment group and 27 cases (46.6%) of the RDS in the control group. There was significant difference between the two groups (P <0.05). The treatment group was significantly better than the control group (P <0.01) in stable condition, respiratory improvement time and cure rate, and was significantly lower than the control group in the incidence of complication and mortality (P <0.05). Conclusion Ambroxol can effectively promote the generation and secretion of pulmonary surfactant, promote lung maturation and improve ventilation. It has obvious curative effect and significance on improving survival rate and quality of life in children.